Skip to main content
Premium Trial:

Request an Annual Quote

Becton Dickinson's Q3 Revenues Rise 3 Percent on Bioscience Gains

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Becton Dickinson today reported 3 percent revenue growth for its third quarter ended June 30, led by double-digit revenue growth for its BD Biosciences business in the US. On a currency-neutral basis, its revenues grew around 9 percent.

The Franklin Lakes, NJ-based maker of medical devices, diagnostics, and life sciences research products brought in total revenues of $1.88 billion for the quarter, compared to $1.82 billion for the third quarter of 2009. The results beat analysts' consensus estimate for revenues of $1.85 billion.

BD's US sales increased 3 percent to $829.6 million from $805.4 million, and its international sales also increased around 3 percent to $1.05 billion from $1.01 billion.

Its BD Medical segment reported revenues of $992.8 million, up nearly 3 percent from $968.7 million for Q3 2009. Its BD Diagnostics segment had 2 percent revenue growth to $576.3 million from $566.4 million, and its BD Biosciences segment had 8 percent growth to $309.1 million from $285.2 million.

Within BD Biosciences, the firm's cell analysis products had around 20 percent revenue growth in the US to $84.4 million from $70.5 million year over year, while its Discovery Labware products sales were up 6 percent to $39.8 million from $37.6 million. Both of those businesses also increased revenues internationally but not as much as in the US, partially due to currency headwinds.

BD's net income for the quarter was $306.9 million, or $1.29 per share, down from $341 million, or $1.39 per share, for Q3 2009. Last year's third quarter included $20 million, or $.08 per share, tax benefit related to tax settlements in various jurisdictions, the firm said. Excluding that benefit, and on a foreign currency-neutral basis, BD's adjusted EPS for Q3 2010 was up 7 percent.

The firm also comfortably beat analysts' estimates for $1.24 per share.

"Despite the challenging global economy, we expect to deliver bottom-line growth of approximately 9 percent foreign-currency neutral, which is in line with our previously communicated range of 8 to 10 percent for the full fiscal year 2010," BD Chairman and CEO Edward Ludwig said in a statement.

BD spent $108.6 million on R&D during the quarter, a 10 percent increase from $98.5 million. Its SG&A spending declined around 2 percent to $423.7 million from $429.9 million.

BD said that it expects to report full-year 2010 revenue growth of approximately 5 percent, which is 1 percent lower than previously expected by the firm. It said the decrease is due to a weaker Euro and overall lower lab testing in the US.

BD also said that it is increasing its share repurchases up to $700 million from $550 million.

In early Thursday trade on the New York Stock Exchange, shares of BD were up 1 percent at $68.89.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.